Abstract: Disclosed is a novel bidentate pyridine transition metal catalyst having the general formula each R is independently selected from hydrogen or C1 to C6 alkyl, or C6 to C14 aryl, each R′ is independently selected from R, C1 to C6 alkoxy, C6 to C14 aryl, C7 to C20 alkaryl, C7 to C20 aralkyl, halogen, or CF3, M is a Group 3 to 10 metal, each X is independently selected from halogen, C1 to C6 alkyl, C6 to C14 aryl, C7 to C20 alkaryl, C7 to C20aralkyl, C1 to C6 alkoxy, or L is X, cyclopentadienyl, C1 to C6 alkyl substituted cyclopentadienyl, indenyl, fluorenyl, or “n” is 1 to 4; “a” is 1 to 3; “b” is 0 to 2; a+b≦3; “c” is 1 to 6; and a+b+c equals the oxidation state of M.

Abstract: The present invention describes catalysts for atom transfer radical polymerization processes. Specifically, a hybrid catalyst system comprising transition metal complexes held in close conjunction with a solid support and of a soluble ligand, or soluble transition metal complex or desorbed catalyst. The hybrid catalyst system may be used in a controlled polymerization process of radically (co)polymerizable monomers in the presence of a system comprising an initiator comprising one or more radically transferable atom(s) or group(s). The catalyst may include a transition metal, one or more counterions, a ligand attached to a solid support, and a soluble ligand. The hybrid catalyst may also be comprised of an attached transition metal complex, and a soluble transition metal complex.

Abstract: Removing silicon species from hydrocarbon solvents such as cyclohexane by flowing the hydrocarbon solvent through a selective adsorbent selected from the group consisting of aluminas, silicon-aluminas, ion exchange resins, zeolite Y, and combinations thereof.

Abstract: This invention discloses a rubbery polymer which is comprised of repeat units that are derived from (1) at least one conjugated diolefin monomer, and (2) at least one functionalized monomer having of the structural formula: wherein R represents an alkyl group containing from 1 to about 10 carbon atoms or a hydrogen atom, and wherein R1 and R2 can be the same or different and represent hydrogen atoms or a moiety of the structural formula: wherein the R3 groups in repeat units and in different repeat units can be the same or different and represent hydrogen atoms or alkyl groups containing from 1 to about 4 carbon atoms, wherein n and x represents integers from 1 to about 10, with the proviso that R1 and R2 can not both be hydrogen atoms.

Abstract: The invention refers to a linear, isotactic polymer which has a structure of one or several C2 to C20 olefins, of which the isotacticity, due to a statistic distribution of stereoscopic errors in the polymer chain, is within the range of from 25 to 60% of [mmmm] pentad concentration with the proviso that an arbitrary or rather regular sequence of isotactic and atactic blocks is excluded, the polymer having a mean molecular weight Mw within the range of from 100,000 to 800,000 gms/mol and a TG of from −50 to +30.

Abstract: Melt-processible, thermoplastic polyethylene compositions of high resistance against wear are disclosed and methods for making and processing same. Additionally, products comprising these compositions are described.

Abstract: This invention relates to the application of fluorinated urethane compositions to stone in order to protect the stone from the deleterious effects of water and pollution.

Abstract: The present invention relates to polyaspartate mixtures containing a) 5 to 50 equiv. %, based on the total equivalents of aspartate groups, of a polyoxypropylene polyaspartate corresponding to the formula wherein X1 represents the residue obtained by removing the amino groups from a polyoxypropylene polyamine having a functionality of n, R1 and R2 are identical or different and represent organic groups which are inert to isocyanate groups at a temperature of 100° C. or less, R3 and R4 are identical or different and represent hydrogen or organic groups which are inert towards isocyanate groups at a temperature of 100° C. or less and n is 2 to 4, and b) 50 to 95 equiv.

Abstract: Claimed is a non-porous, waterproof film having a water vapor permeability of at least 1000 g/m2 day, based on a thermoplastic polyurethane, wherein the polyurethane is composed of a) 40 to 52 wt. % of polyether glycol having an atomic ratio of carbon to oxygen in the range of 2,0 to 4,3, with at least 30 wt. % of the polyurethane being composed of a polyether glycol having an atomic ratio of carbon to oxygen in the range of 2,0 to 2,4, b) 30 to 45 wt. % of polyisocyanate, calculated as 4,4′-diphenyl methane diisocyanate, c) 0,5 to 10 wt. % of araliphatic diol, and d) 5 to 20 wt. % of low-molecular weight chain extender, calculated as 1,4-butane diol, less the amount of araliphatic diol. Also claimed is the use of these films in rainwear, shoes, tents, seats, as mattress covers, as understating, in garments for medical purposes, and for the manufacture thereof of wound dressings.

Abstract: This specification describes an optical polycarbonate composition obtained by the melt polycondensation of a bisphenol and a carbonic diester in the presence of an alkaline compound catalyst, wherein said optical polycarbonate composition comprises (i) a compound expressed by the following Formula [A] in an amount of 30 to 2000 ppm; (ii) a compound expressed by the following Formula [B] in an amount of 30 to 4000 ppm; and (iii) a compound expressed by the following Formula [C] in an amount of 80 to 8000 ppm. The polycarbonate composition has a viscosity average molecular weight of between 12,000 and 18,000, and the portion with a molecular weight (as measured by GPC) of 1000 or less accounts for 0.5 to 1.5 wt %.

Abstract: 100 parts by weight of the polycarbonate produce by melt polycondensation of a carbonic acid diester and a dihydroxy compound and 0.0001 to 0.1 part by weight of a phosphite compound represented by following Formula (I) are formulated: wherein Rs are each one of a hydrogen atom, an alkyl group, an aryl group, and an oxyalkyl group, where the two Rs are not concurrently hydrogen atoms. The process of the invention can yield polycarbonate molding materials that have satisfactory hue and can be used in a wide variety of applications such for optical materials.

Abstract: This invention relates to an extrusion method preparing polycarbonates from a solution of an oligomeric polycarbonate. A mixture of bis(methyl salicyl)carbonate (BMSC), BPA and a transesterification catalyst are first equilibrated at moderate temperatures to provide a solution of polycarbonate oligomer in methyl salicylate. The solution is then fed to a devolatilizing extruder, where the polymerization reaction is completed and the methyl salicylate solvent is removed. The solution comprising the oligomeric polycarbonate can also be pre-heated under pressure to a temperature above the boiling point of methyl salicylate and subsequently fed to a devolatilizing extruder equipped for rapid flashing off the solvent. The method provides polycarbonate with greater efficiency than the corresponding process in which unreacted monomers are fed to the extruder. Additionally, the method of the invention does not require the isolation of a precursor polycarbonate comprising ester-substituted phenoxy terminal groups.

Abstract: The present invention provides a method for easily producing a high-molecular weight polyimide resin at high yield by drying and heating a mixture mixed by material monomers of polyimide.

Abstract: A novel non-aggressive sulfonating process for aromatic polymers is described. The process encompasses: a). dissolving the aromatic polymer in a substantially anhydrous acid selected from the group consisting of concentrated sulfuric acid, chlorosulfonic acid, and oleum, b) adding an organic solvent which is inert under the conditions of the reaction, c) adding a carboxylic anhydride, d) adding a sulfonating agent, and e) carrying out the sulfonation at a temperature below 25° C. and for a time sufficient to achieve the desired degree of sulfonation.

Abstract: A process for obtaining non thermoprocessable fine powders of homopolymer or modified PTFE, comprising the following steps: A) obtaining of the polymer latex under the gel form; B) washing of the polymer gel with acid aqueous solutions or neutral aqueous solutions; C) granulation of the gel washed by mechanical stirring, at a specific power in the range 1.5-10 kW/m3, until flotation of the PTFE fine powder, and separation of the floated fine powder; D) drying in an aerated oven of the floated fine powder at a drying temperature in the range 90° C.-160° C.

Abstract: The present invention is directed to a process for producing a powder free natural latex article and the articles produced by the process. In one embodiment, the process of the present invention may be used to form a powder free natural latex glove which has very low levels of extractable protein without being subjected to a halogenation processes. The process includes forming a natural rubber article on a former and then, either before or after stripping the article from the former, contacting the article with a rinse solution comprising the ionic species of a disassociated metal salt. In one embodiment, the metal salt may be sodium chloride. Contact with the rinse solution may lower protein levels in the latex. When the article is stripped from the former prior to contact with the rinse solution, the rinse solution may also remove any residual powders from the glove in order to produce a powder free natural rubber article.

Abstract: Aromatic polyethers are prepared by displacement polymerization reaction in the presence of a water-immiscible solvent with boiling point at atmospheric pressure of greater than 110° C. and a density ratio to water of greater than 1.1:1 at 20-25° C. The polyethers are purified by processes comprising aqueous extraction, or filtration, or a combination thereof.

Abstract: The invention relates to cyclosporin derivatives, whereby the peptide chain thereof comprises at least one pseudo-proline type non-natural amino acid radical. The invention also relates to a method for the production of said derivatives.

Abstract: The invention provides for proteins correlated with cellular resistance to carboxyamido-triazole (CAI) which have at least one Src homology 3 (SH3) binding domain, and functionally equivalent compounds.

Abstract: The present invention relates to (a) variable regions of heavy and light chains of an antibody specific to a surface antigen in sporozoite of Eimeria spp.; (b) a recombinant scFV (single chain variable fragment) antibody prepared using the variable regions; (c) a method for preparing a recombinant scFv antibody; and (d) an expression vector for expressing a recombinant scFv antibody.

Abstract: The invention relates to novel nucleic acid sequences which encode human autoantibodies and antiidiotypic antibodies against blood platelet membrane proteins, to novel amino acid sequences of human antibodies, and to their use for the diagnosis and therapy of diseases.

Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

Abstract: The present invention relates to an antibody active against a fusion polypeptide comprising a histidine portion, a process for the preparation thereof and its use.

Abstract: Zinc finger proteins of the Cys2His2 type represent a class of malleable DNA binding proteins which may be selected to bind diverse sequences. Typically, zinc finger proteins containing three zinc finger domains, like the murine transcription factor Zif268 and the human transcription factor Sp1, bind nine contiguous base pairs (bp). To create a class of proteins which would be generally applicable to target unique sites within complex genomes, the present invention provides a polypeptide linker that fuses two three-finger proteins. Two six-fingered proteins were created and demonstrated to bind 18 contiguous bp of DNA in a sequence specific fashion. Expression of these proteins as fusions to activation or repression domains allows transcription to be specifically up or down modulated within cells. Polydactyl zinc finger proteins are broadly applicable as genome-specific transcriptional switches in gene therapy strategies and the development of novel transgenic plants and animals.

Abstract: Biologically active drug polymer derivatives, namely peptides or protein derivatives, are useful medicaments and are represented by the generic formula: RO—(CH2—CH2O)n—(CO)—NH—X—(CO)—NH—Z wherein R represents a lower alkyl group, n is an integer between 25 and 250, X when combined with adjcacent NH and CO groups represents a dipeptide residue, and Z when combined with the adjacent group represents a biologically active peptide or protein.

Abstract: A reactive dye compound comprising: (a) at least one chromophore moiety; (b) at least one SO2C2H4 group which is attached to the chromophore moiety either directly via the sulphur atom of the SO2C2H4 group or via a linking group L; characterized in that at least one SO2C2H4 group is substituted on its terminal carbon atom with at least one Y group wherein Y is derived from a hydrated aldehyde, a hydrated ketone, a hydrated alpha-hydroxy ketone or the hydrated form of formic acid, and linked via one of its oxygen atoms to the terminal carbon of the SO2C2H4 group thereby forming a hemiacetal.

Abstract: The present invention relates to a novel protein isolated from the leukocyte of IgA nephropathy patients, and DNA encoding the protein. It also relates to an oligonucleotide based on the nucleotide sequence complementary with the DNA, an antibody which specifically reacts with the protein and, furthermore, diagnostic and therapeutic drugs of IgA nephropathy comprising it.

Abstract: Oligonucleotide probes containing two labels are provided and are useful in hybridization assays. The probes can also contain a minor groove binding group.

Abstract: A method of preparing an immobilized oligonucleotide having a free 3′-end comprises the steps of: i) preparing an oligonucleotide attached in a first position to a solid support via its 3′-end and having a free 5′-end; ii) binding said oligonucleotide in a second position remote from the 3′-end to the solid support; and iii) selectively releasing the 3′-end of the oligonucleotide from the solid support to obta the oligonucleotide attached to the support in said second position in a reversed orientation with a free 3′-end.

Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C—C chemokine designated MDC. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein.

Abstract: The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.

Abstract: Provided is a protein used in the development of a therapeutic agent for neuron- or endocrine cell-related diseases, in which the transport system is involved. The protein has an amino acid sequence with one or more amino acids deleted, substituted, inserted or added relative to the amino acid: sequence set forth under SEQ ID NO:1 in the Sequence Listing and which has a property to interact with GDP/GTP exchange factor II.

Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.

Abstract: The present invention concerns the discovery of a new regulatory mechanism for gene expression in lactic acid bacteria (LAB), especially Lactobacillus sake LTH673 or Lactobacillus plantarium C11, that includes previously unrecognized strongly regulable promoter elements. The essential finding is that the expression of genes under the control of a promoter element dependent on the expression of the IF-K-R gene cluster. The expression of the IF-K-R gene cluster is autoinduced by the secreted peptide encoded by IF, thus providing a regulable expression system for a desired protein. The invention further comprises the purified IF protein.

Abstract: The present invention provides novel compositions comprising Epstein-Barr virus-specific oligonucleotides that are useful as primers to amplify particular regions of the genome during enzymatic nucleic acid amplification. The invention also provides a rapid, sensitive and specific method for the detection and quantitation of the virus which may be present in a clinical specimen, using the virus-specific primers and enzymatic nucleic acid amplification; hybridization of amplified target sequences, if present, with one or more Epstein-Barr virus-specific oligonucleotide probes which are labeled with a detectable moiety; and detection of the detectable moiety of labeled oligonucleotide probe hybridized to amplified target sequences of Epstein-Barr virus DNA.

Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Abstract: A microorganism that is a mutant bacterial strain of the species Actinosynnema pretiosum, designated PF4-4, (ATCC PTA-3921), being capable of producing maytansinoid ansamitocins such as ansamitocin P-3 in improved yield compared to previous known strains, and capable of growth under varied culture conditions, and methods of producing maytansinoid ansamitocins by culturing PF4-4 in a suitable growth medium.

Abstract: The invention relates to the preparation of compounds (I) in which A═H or acyl and R1, R2, R3, R, n, X, Y and Z are as defined in claim 1 by halogenation and rearrangement of compounds (II) (optionally salt) to give compounds (III) a) ammonolysis of (III) to (IV), reduction of the nitro group and reaction with carbamate (salts) (VI) of the formula Ar—OCO—N(M)-Het, where Ar=phenyl, M═H or cation and Het=heterocycle from formula (I), to give compounds (I) (A═H), or b) ammonolysis of (III) to (IV), reaction with carbamate (salt) (VI) and reduction of resulting compounds (VII) at the NO2 group to give compounds (I) (A═H), or c) reaction of (III) with cyanates and amines (VII) of the formula HNR3-Het and reduction of the resulting compound (VII) at the NO2 group to give compounds (I) (A═H) and optional acylation if A is to be other than H.

Abstract: The invention relates to a method for producing pure melamine. According to this method, the melamine melt, which is produced from urea in a high-pressure process, is cooled and ammonia is added until it reaches a temperature of approximately 1 to 50° C. above the melting temperature of the melamine as dependent on the respective pressure of ammonia and then either a) quenched with water or an aqueous solution or suspension containing ammonia and/or melamine so that the melamine solidifies or b) quenched with cold liquid or gaseous ammonia, so that the melamine solidifies, the melamine then being cooled further with water or an aqueous solution or suspension containing ammonia and/or melamine and c) the melamine is then isolated.

Abstract: The invention provides compounds of formula I, R1—OP(O)(OH)2  I wherein R1 represents the non-hydroxy portion of a triazole antifungal compound of the type comprising a tertiary hydroxy group; or a pharmaceutically acceptable salt thereof. The compounds of the invention are useful in the treatment of fungal infections, and have good aqueous solubility.

Abstract: Compounds of the following formula are provided: wherein: R1 is —X—R1′; in which R1′ is alkyl, cycloalkyl, aryl, aralkyl, hetaryl, or heterocyclyl, all of which are optionally substituted; X is —NH; R2 is optionally substituted lower alkyl; and R3 is —NR4R5; in which R4 and R5 independently are hydrogen or lower alkyl optionally substituted by hydroxy or amino; or acid addition salts or cationic salts thereof. The compounds inhibit CDK-2 activity and are useful for treating disorders characterized by undesirable cell proliferation.

Abstract: Thebaine is manufactured in high yields and with a high purity using codeine or a salt of codeine as the starting material. The manufacturing process involves the following steps: (a) codeine or a codeine salt (e.g., codeine phosphate) is converted into the intermediate N-carboalkoxy- or N-carboaryloxynorcodeine; (b) the intermediate N-carboalkoxy- or N-carboaryloxynorcodeine resulting from step (a) is oxidized to yield the intermediate N-carboalkoxy- or N-carboaryloxynorcodeine; (c) the intermediate N-carboalkoxy- or N-carboaryloxynorcodeinone resulting from step (b) is enolized with a base and the resultant enolate is thereafter methylated to yield the intermediate N-carboalkoxy- or N-carboaryloxynorthebaine; and (d) the intermediate N-carboalkoxy- or N-carboaryloxynorthebaine resulting from step (c) is reduced to yield thebaine.

Abstract: The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.

Abstract: A method of preparing intermediates for making 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines is disclosed.

Abstract: A composition for protecting human skin from harmful effects of the sun, the composition comprising a topically effective amount of: (a) a first chemical compound that absorbs ultraviolet light sufficiently to reduce significantly the damage to human skin from harmful effects of ultraviolet light; and (b) a second chemical compound having the formula: (Q-L-Q)w+2Xy−z wherein: Q represents 4-E-2-R3-1-quinolinium; E represents NR1R2, COO R1, OR1, I, Br, Cl, F, or NO3 N represents a nitrogen atom; R1 and R2 independently represent hydrogen or lower alkyl; R3 represents E, hydrogen or lower alkyl; L represents a chain comprising n atoms, the atoms in the chain being t carbon atoms and 0 to approximately 0.5t heteroatoms; the minimum value of n is 12; the maximum value of n is 22; X represents an anion; and w represents 1 or 3, y represents 1 or 2 and z represent 1, 2 or 3, with the proviso that 2w=yz.

Abstract: An E-isomeric fulleropyrrolidine compound of formula (I): is disclosed. Also disclosed is a method for preparing and polymers prepared from such a compound.

Abstract: The present invention provides a method of producing 7-azabicyclo[4.1.0]hept-3-ene-3-carboxylic acid ester (VII) economically, industrially advantageously and efficiently in a large amount.

Abstract: Combinatorial libraries are disclosed which are represented by Formula I: (T′—L)q—Ŝ—C(O)—L′—II′  I wherein: Ŝ is a solid support; T′—L— is an identifier residue; and —L′—II′ is a ligand/linker residue. These libraries contain dihydrobenzopyrans of the formula: which interact (i.e., as agonists or antagonists) with &agr; adrenergic receptors, dopamine receptors, &dgr;-opiate receptors, and K+ channels and are inhibitors of carbonic anhydrase isozymes. They are useful in the treatement of ocular diseases such as glaucoma.

Abstract: Disclosed and claimed are cocoa extracts such as polyphenols or procyanidins, methods for preparing such extracts, as well as uses for them, especially as antineoplastic agents and antioxidants. Disclosed and claimed are antineoplastic compositions containing cocoa polyphenols or procyanidins and methods for treating patients employing the compositions. Additionally disclosed and claimed is a kit for treating a patient in need of treatment with an antineoplastic agent containing cocoa polyphenols or procyanidins as well as a lyophilized antineoplastic composition containing cocoa polyphenols or procyanidins. Further, disclosed and claimed is the use of the invention in antioxidant, preservative and topiosomerase-inhibiting compositions and methods.

Abstract: The invention concerns a novel method for preparing vitamin E. More particularly, it concerns a novel method for the condensation of trimethylhydroquinone and isophytol.